These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

777 related articles for article (PubMed ID: 27145382)

  • 1. Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion.
    Otvos B; Silver DJ; Mulkearns-Hubert EE; Alvarado AG; Turaga SM; Sorensen MD; Rayman P; Flavahan WA; Hale JS; Stoltz K; Sinyuk M; Wu Q; Jarrar A; Kim SH; Fox PL; Nakano I; Rich JN; Ransohoff RM; Finke J; Kristensen BW; Vogelbaum MA; Lathia JD
    Stem Cells; 2016 Aug; 34(8):2026-39. PubMed ID: 27145382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression.
    Alban TJ; Bayik D; Otvos B; Rabljenovic A; Leng L; Jia-Shiun L; Roversi G; Lauko A; Momin AA; Mohammadi AM; Peereboom DM; Ahluwalia MS; Matsuda K; Yun K; Bucala R; Vogelbaum MA; Lathia JD
    Front Immunol; 2020; 11():1191. PubMed ID: 32625208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
    Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Bossman SA; Ter Laan M; Wesseling P; Adema GJ
    Neuro Oncol; 2016 Sep; 18(9):1253-64. PubMed ID: 27006175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulating glioma-mediated myeloid-derived suppressor cell development with sulforaphane.
    Kumar R; de Mooij T; Peterson TE; Kaptzan T; Johnson AJ; Daniels DJ; Parney IF
    PLoS One; 2017; 12(6):e0179012. PubMed ID: 28666020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host derived macrophage migration inhibitory factor expression attenuates anti-tumoral immune cell accumulation and promotes immunosuppression in the tumor microenvironment of head and neck squamous cell carcinoma.
    Ryan N; Lamenza F; Shrestha S; Upadhaya P; Springer A; Jordanides P; Pracha H; Roth P; Kumar R; Wang Y; Vilgelm AE; Satoskar A; Oghumu S
    Biochim Biophys Acta Mol Basis Dis; 2024 Oct; 1870(7):167345. PubMed ID: 38992847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis.
    Alban TJ; Alvarado AG; Sorensen MD; Bayik D; Volovetz J; Serbinowski E; Mulkearns-Hubert EE; Sinyuk M; Hale JS; Onzi GR; McGraw M; Huang P; Grabowski MM; Wathen CA; Ahluwalia MS; Radivoyevitch T; Kornblum HI; Kristensen BW; Vogelbaum MA; Lathia JD
    JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
    Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
    Front Immunol; 2021; 12():637146. PubMed ID: 34025646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune consequences of penfluridol treatment associated with inhibition of glioblastoma tumor growth.
    Ranjan A; Wright S; Srivastava SK
    Oncotarget; 2017 Jul; 8(29):47632-47641. PubMed ID: 28512255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2
    Takacs GP; Kreiger CJ; Luo D; Tian G; Garcia JS; Deleyrolle LP; Mitchell DA; Harrison JK
    Front Immunol; 2022; 13():993444. PubMed ID: 36685592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.
    Lee-Chang C; Rashidi A; Miska J; Zhang P; Pituch KC; Hou D; Xiao T; Fischietti M; Kang SJ; Appin CL; Horbinski C; Platanias LC; Lopez-Rosas A; Han Y; Balyasnikova IV; Lesniak MS
    Cancer Immunol Res; 2019 Dec; 7(12):1928-1943. PubMed ID: 31530559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation.
    Ai L; Mu S; Sun C; Fan F; Yan H; Qin Y; Cui G; Wang Y; Guo T; Mei H; Wang H; Hu Y
    Mol Cancer; 2019 Apr; 18(1):88. PubMed ID: 30979371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer.
    Zhang H; Ye YL; Li MX; Ye SB; Huang WR; Cai TT; He J; Peng JY; Duan TH; Cui J; Zhang XS; Zhou FJ; Wang RF; Li J
    Oncogene; 2017 Apr; 36(15):2095-2104. PubMed ID: 27721403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
    Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
    Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma.
    Richard SA
    Dis Markers; 2020; 2020():8844313. PubMed ID: 33204365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-608 inhibits the migration and invasion of glioma stem cells by targeting macrophage migration inhibitory factor.
    Wang Z; Xue Y; Wang P; Zhu J; Ma J
    Oncol Rep; 2016 May; 35(5):2733-42. PubMed ID: 26935642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.
    Soong RS; Anchoori RK; Yang B; Yang A; Tseng SH; He L; Tsai YC; Roden RB; Hung CF
    Oncotarget; 2016 Oct; 7(42):68489-68502. PubMed ID: 27655678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutualistic Effects of the Myeloid-Derived Suppressor Cells and Cancer Stem Cells in the Tumor Microenvironment.
    Tanriover G; Aytac G
    Crit Rev Oncog; 2019; 24(1):61-67. PubMed ID: 31679221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
    De Cicco P; Ercolano G; Ianaro A
    Front Immunol; 2020; 11():1680. PubMed ID: 32849585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.